Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters

Cerebrovascular Diseases
Edaravone Acute Infarction Study Group

Abstract

Edaravone, a novel free radical scavenger, demonstrates neuroprotective effects by inhibiting vascular endothelial cell injury and ameliorating neuronal damage in ischemic brain models. The present study was undertaken to verify its therapeutic efficacy following acute ischemic stroke. We performed a multicenter, randomized, placebo-controlled, double-blind study on acute ischemic stroke patients commencing within 72 h of onset. Edaravone was infused at a dose of 30 mg, twice a day, for 14 days. At discharge within 3 months or at 3 months after onset, the functional outcome was evaluated using the modified Rankin Scale. Two hundred and fifty-two patients were initially enrolled. Of these, 125 were allocated to the edaravone group and 125 to the placebo group for analysis. Two patients were excluded because of subarachnoid hemorrhage and disseminated intravascular coagulation. A significant improvement in functional outcome was observed in the edaravone group as evaluated by the modified Rankin Scale (p = 0.0382). Edaravone represents a neuroprotective agent which is potentially useful for treating acute ischemic stroke, since it can exert significant effects on functional outcome as compared with placebo.

References

Apr 10, 2012·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Tao YangYujian Liu
Jul 26, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Martin CederlundBo Akerström
Aug 5, 2005·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Tomonosuke SomeyaYuichiro Yamashiro
Sep 17, 2005·The Japanese Journal of Thoracic and Cardiovascular Surgery : Official Publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai Zasshi·Kenichi HashizumeRyohei Yozu
May 10, 2013·Journal of Molecular Neuroscience : MN·Bing LiZhiying Xu
Dec 11, 2007·Molecular Neurobiology·Venkata Prasuja NakkaRam Raghubir
Jun 15, 2011·Translational Stroke Research·Paul A Lapchak
Jul 10, 2013·European Journal of Medicinal Chemistry·Mingna SunGang Liu
Jul 13, 2013·Cell Death & Disease·Y YangL Liu
Nov 23, 2006·Journal of Neurotrauma·Kenji DohiTohru Aruga
Jan 1, 2008·Acta Crystallographica. Section E, Structure Reports Online·Qiang WangFeng Zhi
Jan 22, 2009·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Masaharu Hayashi
Jan 12, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·X LiuG Zhao
Nov 19, 2009·Journal of Translational Medicine·Shaheen E LakhanMagdalena Hofer
Nov 5, 2010·Biological & Pharmaceutical Bulletin·Satomi Koya-MiyataShigeharu Fukuda
Mar 31, 2004·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Toshiaki WatanabeAkihiro Tobe
Jun 27, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Kenichi TsujitaHisao Ogawa
Oct 30, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Ei IkegamiShunichi Ogawa
Oct 16, 2009·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Kazuo Kitagawa
Jul 31, 2007·Drugs & Aging·Chen X Wang, Ashfaq Shuaib
May 18, 2005·Internal Medicine·Kazunori OkadaJapanese Standard Stroke Registry Study (JSSRS) Group
Apr 6, 2006·Internal Medicine·Yasuhisa Kitagawa

Related Concepts

Ischemic Cerebrovascular Accident
Exertion
Disseminated Intravascular Coagulation
Phenylmethylpyrazolone
Memory for Designs Test
Free Radicals
MCI 186
Neuroprotective Agents
Acute Disease
Pyramidone

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.